Background: Invasive candidiasis (IC) is a common cause of mortality in solid organ transplant recipients (OTRs), but knowledge of epidemiology in this population is limited.
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included infection site, culture data, method of diagnosis, date and type of transplant, history of rejection, comorbid conditions, cytomegalovirus infection (based on tissue histopathology or viremia), recent immunosuppressive and antifungal treatment data, and patient status at least 3-months after initial diagnosis of IC infection.
Microbiologic methods
Available cultures and histopathological specimens were processed at the participating hospitals. Species identification was performed using routine methods at the participants' affiliated laboratories. Available fungal isolates were forwarded to the Centers for Disease
Control Mycotic Diseases Branch for confirmation of identification.
Data analysis
Univariate analyses to assess the relationship between variables and survival were performed by tabulating these measures in the survivor and non-survivor cohorts. The χ 2 test or the Fisher exact test was used to assess statistical significance for categorical variables and the Wilcoxon rank-sum test was used for continuous variables. Multivariable analyses of factors associated with mortality were performed using stepwise multiple logistic regression via generalized estimating equations. We chose to model the correlation of the repeated measures on some of the individuals with a compound symmetry covariance structure. The criterion for entry into the model was significance at α = 0.20, whereas the criterion for remaining in the model was significance at α = 0.05. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. A multiple logistic regression model containing the best predictor variables obtained from the stepwise analysis was then run using all available data in order to obtain more robust estimates of
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the ORs, 95% CIs, and P-values. Once final models were achieved through the stepwise process, a potential interaction between prednisone use and rejection was evaluated by incorporating an interaction term into the final model.
A time-to-death analysis was also performed. First, a univariate analysis comparing transplant type, and another comparing Candida species were conducted via Kaplan-Meier estimation and the log-rank test. To validate the above logistic regression results, multivariate analyses were run using Cox regression incorporating the final model terms found in logistic models. All statistical tests were 2-tailed and were performed using a 5% significance level (α = 0.05). Statistical analyses were performed using the R statistical computing environment, version 2.11. 
RESULTS

Epidemiology of IC among OTRs
Characteristics of IC among Candida species
Survival by Candida species varied as shown in Figure 1 . Table 2) . Triazole antifungal use prior to infection was linked to C. glabrata infection. [18] [19] [20] The patient age associated with C. glabrata in this cohort was 49 years. [21] [22] [23] [24] An additional treatment variable associated with C. glabrata infection was use of methyprednisolone (MPS).
We also compared patients with C. albicans (n = 296) to those with the aggregate non-albicans species population (n = 258). Independent risk factors for IC caused by nonalbicans species were similar to those for C. glabrata alone and included black race, female
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OTRs. Use of these agents was observed predominantly in the liver transplant cohort (amphotericin 33/261 12.6% and echinocandin 14/261 5.4%).
Triazoles were the most common antifungal drugs used for treatment of IC. This treatment was particularly frequent in pancreas (28/38; 73.7%) and kidney transplant recipients (158/224; 70.5%). Additional characteristics in the different transplant types are shown in Supplemental Table S1 .
Predictors of mortality in patients with IC
Ninety-day mortality for all patients was 168/635 (26.5%). Kaplan-Meier estimate of 30-day survival was 85.5%. Survival was statistically different among Candida species ( Figure 1 ). 
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toward reduced efficacy with this antifungal drug class for C. parapsilosis infection (61.1% in those that died vs. 30.3% in survivors, P = 0.03). Among the renal transplant cohort, the use of AmB was linked to poor outcome (42% in those who died vs. other 21.8% in survivors, P <0.001).
DISCUSSION
Infection with Candida species was the most common invasive fungal infection among the TRANSNET solid organ transplant population. 14 Against this backdrop, we found that, similar to other epidemiologic studies of IC, C.
albicans remained the most frequent pathogen. However, >10% of cases included infection with 2 or more Candida species. The frequency in the present study is more than twice that previously reported. 21,25-28 Similar to prior reports, this epidemiologic feature did not impact outcome in this cohort. Over the last 2 decades, the proportion of non-albicans Candida species causing IC has steadily increased. 9, 26, [29] [30] [31] [32] [33] The second most common pathogen in the
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present study was C. glabrata. [34] [35] [36] The relevance of this increase in non-albicans infections relates to potential for reduced treatment efficacy with certain antifungals owing to differences in susceptibility, in particular, the reduced susceptibility of C. glabrata and C.
parapsilosis to triazole and echinocandin antifungal drugs, respectively. 37-40 Antifungal susceptibility testing of available isolates demonstrated elevated minimum inhibitory concentrations for these species and drug combinations. 40 Interestingly, outcome for patients infected with non-albicans species in this transplant cohort was worse than for those with disease caused by C. albicans.
It is notable that we found prophylactic use of drugs from the triazole and echinocandin classes was common for C. glabrata and C. parapsilosis infections and was statistically associated with poorer outcome for these 2 species. The apparent superiority of the echinocandin class for treatment of IC, including infection caused by C. glabrata, has been observed in recent analysis. 41 Reduced efficacy for this class against less susceptible species, such as C. parapsilosis, has not been evident in clinical trials. 38, 42, 43 It is possible that the advanced degree of immunosuppression in this cohort, as suggested by the high rate of both multi-organ failure and allograft rejection, raised the therapeutic hurdle for this pathogen, which is traditionally considered among the least virulent. Indeed, the mortality rate in the transplant population infected with C. parapsilosis was unusually high compared to previous reports. 44 7, 12, 52, 53 The impact of the pulmonary infection site on outcome is intriguing, but the relevance unclear. We speculate this could be an indication of dissemination or simply a high burden of Candida, as suggested in prior colonization studies.
Examination of antifungal choice for prophylaxis and therapy in the current population revealed a use pattern consistent with prior surveys. 12, 21, 55, 56 Prophylaxis was dominated by the triazole class, predominantly fluconazole. Definitive treatment represented a mixed approach, and included a high percentage of echinocandins and comparatively little use of polyenes, probably owing to the differential risk for
nephrotoxicity. Triazole prophylaxis in this cohort was successful in the prevention of IC by C. albicans, as previously reported. However, the rate of breakthrough IC cases in this cohort was striking. Analyses demonstrated that many emergent infections were caused by species with higher minimum inhibitory concentrations to antifungal compounds. 42 In the setting of triazole prophylaxis, infection with C. glabrata was common. This observation is congruent with previously reported prophylaxis studies. 18 Interestingly, we also found an association between echinocandin prophylaxis and infection with C. parapsilosis (6/52, 11.5%), and this finding is consistent with the reduced efficacy described in the setting of definitive therapy described above.
A number of comorbidities were strongly related to poor outcomes. Neutropenia, heart failure, and renal and hepatic dysfunction each conferred a negative impact on outcome. Interestingly, we found a disparate impact for 2 corticosteroid formulations, prednisone and MPS. As noted above, we theorize that use of MPS is a marker of rejection and this likely translates into a risk for poor outcome. Conversely, use of prednisone may suggest stable allograft function and may explain the observed 'protective' nature of this therapy. Early disease was also predictive of a favorable outcome. We theorize this improvement may be a result of earlier diagnosis linked to enhanced vigilance in the early post-transplant period.
The results of this survey both confirm and extend our understanding of the features of IC in solid OTRs. We identified a hierarchy of risk for disease and outcome based on transplant type, underlying disease, and comorbid conditions. We did not identify directly modifiable factors, other than an emphasis on the importance of drug selection for certain
Candida species, which is intuitive based upon fairly predictable antifungal drug susceptibility. Current evidence suggests that echinocandins are the optimal empiric
antifungal drug choice for IC. 43 In the current study, this benefit is less clear for infection 
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